Scalper1 News
British pharma giant AstraZeneca (AZN) announced a new drug approval Tuesday and rolled out a strategy to nearly double revenue over the next decade, furthering its quest to convince shareholders not to yield to Pfizer’s (PFE) takeover attempt. Shareholders did not seem excited, however, as AstraZeneca’s stock was down a fraction on the stock market today. Astra said that the FDA had approved Epanova, a treatment for severe hypertriglyceridaemia, Scalper1 News
Scalper1 News